Reversibility of antibiotic resistance

Upsala Journal of Medical Sciences

Volumn 119, Issue 2, 2014, Pages 142-148

  Sundqvist, Martin ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic resistance; Fitness; Intervention

Indexed keywords

ANTIBIOTIC RESISTANCE; CROSS INFECTION; HUMAN; TRANSMISSION;

CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 84900861351     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2014.903323     Document Type: Review

References (75)

1. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother. 2000;44:1771-7.
2. Barlow M. What antimicrobial resistance has taught us about horizontal gene transfer. Methods Mol Biol. 2009;532:397-411.
3. Hawkey PM. Molecular epidemiology of clinically significant antibiotic resistance genes. Br J Pharmacol.2008;153:S406-13.
4. Hughes VM, Datta N. Conjugative plasmids in bacteria of the 'pre-antibiotic' era. Nature. 1983;302:725-6.
5. Datta N, Hughes VM. Plasmids of the same Inc groups in Enterobacteria before and after the medical use of antibiotics. Nature. 1983;306:616-17.
6. Nagaev I, Bjorkman J, Andersson DI, Hughes D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol. 2001;40:433-9.
7. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother. 2002;46:1204-11.
8. Gustafsson I, Cars O, Andersson DI. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J Antimicrob Chemother. 2003;52:258-63.
9. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother. 2005;49:2343-51.
10. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944-6.
11. Nilsson AI, Zorzet A, Kanth A, Dahlstrom S, Berg OG, Andersson DI. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci USA. 2006;103:6976-81.
12. Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother. 2008;62:495-503.
13. Schrag SJ, Perrot V, Levin BR. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc Biol Sci. 1997; 264:1287-91.
14. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 2009;5:e1000541.
15. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev. 2002;15:647-79.
16. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4- ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;61:273-81.
17. Johnson JR, Murray AC, Kuskowski MA, Schubert S, Prère MF, Picard B, et al. Distribution and characteristics of Escherichia coli clonal group A. Emerg Infect Dis. 2005;11:141-5.
18. Osterlund A, Eden T, Olsson-Liljequist B, Haeggman S, Kahlmeter G. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand J Infect Dis. 2002;34:729-34.
19. Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother. 2003;52:128-31.
20. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother. 1997; 41:363-73.
21. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997;337:441-6.
22. Kristinsson KG. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist. 1997;3:117-23.
23. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003;47:2850-8.
24. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci USA. 2000;97:1938-43.
25. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L, et al. The population genetics of antibiotic resistance. Clin Infect Dis. 1997;24:S9-16.
26. Enne VI, Delsol AA, Davis GR, Hayward SL, Roe JM, Bennett PM. Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. J Antimicrob Chemother. 2005;56:544-51.
27. Marciano DC, Karkouti OY, Palzkill T. A fitness cost associated with the antibiotic resistance enzyme SME-1 beta-lactamase. Genetics. 2007;176:2381-92.
28. Johnsen PJ, Simonsen GS, Olsvik O, Midtvedt T, Sundsfjord A. Stability, persistence, and evolution of plasmid-encoded van A glycopeptide resistance in Enterococci in the absence of antibiotic selection in vitro and in gnotobiotic mice. Microb Drug Resist. 2002;8:161-70.
29. Enne VI, Bennett PM, Livermore DM, Hall LM. Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. J Antimicrob Chemother. 2004; 53:958-63.
30. Yates CM, Shaw DJ, Roe AJ, Woolhouse ME, Amyes SG. Enhancement of bacterial competitive fitness by apramycin resistance plasmids from non-pathogenic Escherichia coli. Biol Lett. 2006;2:463-5.
31. Dahlberg C, Chao L. Amelioration of the cost of conjugative plasmid carriage in Eschericha coli K12. Genetics. 2003;165: 1641-9.
32. Mroczkowska JE, Barlow M. Fitness trade-offs in blaTEM evolution. Antimicrob Agents Chemother. 2008;52:2340-5.
33. Bean DC, Livermore DM, Hall LM. Plasmids imparting sulfonamide resistance in Escherichia coli: implications for persistence. Antimicrob Agents Chemother.2009;53:1088-93.
34. Karami N, Nowrouzian F, Adlerberth I, Wold AE. Tetracycline resistance in Escherichia coli and persistence in the infantile colonic microbiota. Antimicrob Agents Chemother. 2006;50:156-61.
35. Sears HJ, Janes H, Saloum R, Brownlee I, Lamoreaux LF. Persistence of individual strains of Escherichia coli in man and dog under varying conditions. J Bacteriol. 1956;71:370-2.
36. Tacconelli E, De Angelis G, Cataldo MA, Mantengoli E, Spanu T, Pan A, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother. 2009;53:4264-9.
37. Perron GG, Gonzalez A, Buckling A. Source-sink dynamics shape the evolution of antibiotic resistance and its pleiotropic fitness cost. Proc Biol Sci. 2007;274:2351-6.
38. Babiker HA. Seasonal fluctuation of drug-resistant malaria parasites: a sign of fitness cost. Trends Parasitol. 2009;25: 351-2.
39. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2009;106: 14711-15.
40. Poulsen HO, Johansson A, Granholm S, Kahlmeter G, Sundqvist M. High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread. J Antimicrob Chemother. 2013;68:1974-7.
41. Johnsen PJ, Townsend JP, Bohn T, Simonsen GS, Sundsfjord A, Nielsen KM. Factors affecting the reversal of antimicrobial-drug resistance. Lancet Infect Dis. 2009;9: 357-64.
42. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2920-5.
43. Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother. 2004;53:853-9.
44. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699-706.
45. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, et al. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother. 2007;60:629-37.
46. Tängdén T, Eriksson B-M, Melhus Å, Svennblad B, Cars O. Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumonia. J Antimicrob Chemother. 2011;66:1161-7.
47. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280:1233-7.
48. Nijssen S, Fluit A, van de Vijver D, Top J, Willems R, Bonten MJM. Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria. Intensive Care Med. 2011;36:512-19.
49. Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, et al. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. PLoS One. 2013;8:e54190.
50. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibioticresistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63:568-74.
51. Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004;42:4769-75.
52. Valverde A, Grill F, Coque TM, Pintado V, Baquero F, Cantón R, et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase- producing organisms in household contacts of infected community patients. J Clin Microbiol. 2008;46:2796-9.
53. Tacconelli E. New strategies to identify patients harbouring antibiotic-resistant bacteria at hospital admission. Clin Microbiol Infect. 2006;12:102-9.
54. Kataja J, Huovinen P, Muotiala A, Vuopio-Varkila J, Efstratiou A, Hallas G, et al. Clonal spread of group A streptococcus with the new type of erythromycin resistance. Finnish Study Group for Antimicrobial Resistance. J Infect Dis. 1998;177:786-9.
55. Arason VA, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. The role of antimicrobial use in the epidemiology of resistant pneumococci: a 10-year follow up. Microb Drug Resist. 2006;12:169-76.
56. Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist. 2002;8:187-92.
57. Koh E, Kim S. Decline in erythromycin resistance in group A Streptococci from acute pharyngitis due to changes in the emm Genotypes rather than restriction of antibiotic use. Korean J Lab Med. 2010;30:485-90.
58. Rudolf D, Michaylov N, van der Linden M, Hoy L, Klugman KP, Welte T, et al. International Pneumococcal clones match or exceed the fitness of other strains despite the accumulation of antibiotic resistance. Antimicrob Agents Chemother. 2011;55:4915-17.
59. Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runehagen A, Cars H, et al. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother. 2010;65:350-60.
60. Levin BR, Perrot V, Walker N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics. 2000;154:985-97.
61. Bjorkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science. 2000;287:1479-82.
62. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet. 2001;357:1325-8.
63. Bean DC, Livermore DM, Papa I, Hall LM. Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005;56:962-4.
64. Chiew YF, Yeo SF, Hall LM, Livermore DM. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. J Antimicrob Chemother. 1998;41:247-51.
65. Butler CC, Dunstan F, Heginbothom M, Mason B, Roberts Z, Hillier S, et al. Containing antibiotic resistance: decreased antibiotic-resistant coliform urinary tract infections with reduction in antibiotic prescribing by general practices. Br J Gen Pract. 2007;57:785-92.
66. Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis. 2009;49:869-75.
67. Imöhl M, Reinert RR, Mutscher C, van der Linden M. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol. 2010;10: 299.
68. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83-93.
69. Sierra JMMDP, Sanchez FMDP, Castro PMD, Salvadó M, de la Red G, Libois A, et al. Group A Streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003. Medicine (Baltimore). 2006;85:139-46.
70. Crum NF, Barrozo CP, Chapman FA, Ryan MAK, Russell KL. An outbreak of conjunctivitis due to a novel unencapsulated Streptococcus pneumoniae among military trainees. Clin Infect Dis. 2004;39:1148-54.
71. Tan CG, Ostrawski S, Bresnitz EA. A preventable outbreak of Pneumococcal pneumonia among unvaccinated nursing home residents in New Jersey during 2001. Infect Control Hosp Epidemiol. 2003;24:848-52.
72. Hoti F, Erasto P, Leino T, Auranen K. Outbreaks of Streptococcus pneumoniae carriage in day care cohorts in Finland - implications for elimination of transmission. BMC Infect Dis. 2009;9:102.
73. Alexander TW, Inglis GD, Yanke LJ, Topp E, Read RR, Reuter T, et al. Farm-to-fork characterization of Escherichia coli associated with feedlot cattle with a known history of antimicrobial use. Int J Food Microbiol. 2010;137:40-8.
74. Li S, Eisenberg JNS, Spicknall IH, Koopman JS. Dynamics and control of infections transmitted from person to person through the environment. Am J Epidemiol. 2009;170:257-65.
75. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D, et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 2011;7:e1002158.